seekingalpha.com
Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript
Neurocrine Biosciences, Inc.NBIXNASDAQ
Loading
Latest News
prnewswire.com
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer.
defenseworld.net
CreativeOne Wealth LLC Has $1.10 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
CreativeOne Wealth LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 34.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,815 shares of the company's stock after selling 4,120 shares during the period. CreativeOne Wealth LLC's holdings in Neurocrine Biosciences
prnewswire.com
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com.
seekingalpha.com
Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript
prnewswire.com
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued.
defenseworld.net
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX
Focus Partners Advisor Solutions LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 152.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,263 shares of the company's stock after purchasing an additional 8,011 shares during the period. Focus Partners Advisor
seekingalpha.com
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
prnewswire.com
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: TD Cowen 46th Annual Health Care Conference. Fireside chat on Tuesday, March 3, 2026 at 11:50 AM ET in Boston Leerink Global Healthcare Conference.
247wallst.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Domino’s Pizza, KeyCorp, Qualcomm, and More
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation, which the President raised to 15% from 10% over the weekend after the Supreme Court struck it down last Friday, was one of... Here Are Tuesday's Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Domino's Pizza, KeyCorp, Qualcomm, and More.
zacks.com
New Strong Sell Stocks for February 18th
COIN, NBIX and UPST have been added to the Zacks Rank #5 (Strong Sell) List on February 18th, 2026.
defenseworld.net
JPMorgan Chase & Co. Has $664.02 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
JPMorgan Chase and Co. increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 11.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,730,152 shares of the company's stock after purchasing an additional 468,405 shares during the period. JPMorgan
seekingalpha.com
Neurocrine Biosciences: Growth Beyond Just Ingrezza
Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, including muscarinic agonist and glutamate modulator programs, appears significantly underappreciated by the market. Ingrezza's revenue growth is slowing due to pricing pressures, but NBIX's robust cash position and pipeline investments support long-term growth into the 2030s.
benzinga.com
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
Neurocrine Biosciences Inc (NASDAQ: NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.
seekingalpha.com
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting
Neurocrine Biosciences reported largely in-line Q4 results, with better-than-expected Crenessity sales; guidance for 2026 was in-line with published expectations but arguably a bit lackluster. NBIX's pipeline is deepening, but meaningful clinical catalysts are unlikely before 2027, when Phase III readouts in MDD and schizophrenia are expected. Absent clinical updates, Street concerns over future pricing pressure on Ingrezza could drive muted market performance, but a recent head-to-head study versus Austedo could drive some upside.
seekingalpha.com
Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
zacks.com
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $1 per share a year ago.
prnewswire.com
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ended December 31, 2025. "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, more diversified biopharmaceutical company," said Kyle W.
zacks.com
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.